New hope for elderly leukemia patients: which chemo works best?
NCT ID NCT06066242
First seen May 15, 2026 · Last updated May 24, 2026 · Updated 3 times
Summary
This study compares two chemotherapy regimens for adults aged 60-75 newly diagnosed with acute myeloid leukemia (AML) who can tolerate intensive treatment. About 90 participants will be randomly assigned to one of three groups to see which approach leads to better event-free survival and remission rates. The goal is to identify the most effective and safe induction therapy for this age group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.